Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine

Detalles Bibliográficos
Autores principales: Liu, Zhigang, Alexander, James L., Lin, Kathy Weitung, Ahmad, Tariq, Pollock, Katrina M., Powell, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the AGA Institute 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578965/
https://www.ncbi.nlm.nih.gov/pubmed/36270334
http://dx.doi.org/10.1053/j.gastro.2022.10.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578965/
https://www.ncbi.nlm.nih.gov/pubmed/36270334
http://dx.doi.org/10.1053/j.gastro.2022.10.010

Ejemplares similares